Lung transplantation for bronchiolitis obliterans syndrome after allo-SCT
(2013) In Bone Marrow Transplantation 48(5). p.703-707- Abstract
- Chronic GVHD (cGVHD) associated bronchiolitis obliterans syndrome (BOS) is a serious complication after allo-SCT, and lung transplantation (LTx) may be the ultimate treatment option. To evaluate this treatment, data on all patients with LTx after allo-SCT ever performed in Sweden, Norway, Denmark and Finland were recorded and compared with survival data from the Scandiatransplant registry. In total, LTx after allo-SCT had been performed in 13 patients. Allo-SCT was done because of AML (n = 6), CML (n = 3), ALL (n = 2), immunodeficiency (n = 1) and aplastic anemia (n = 1). All developed clinical cGVHD, with median interval from allo-SCT to LTx of 8.2 (0.7-16) years. Median age at LTx was 34 (16-55) years, and the median postoperative... (More)
- Chronic GVHD (cGVHD) associated bronchiolitis obliterans syndrome (BOS) is a serious complication after allo-SCT, and lung transplantation (LTx) may be the ultimate treatment option. To evaluate this treatment, data on all patients with LTx after allo-SCT ever performed in Sweden, Norway, Denmark and Finland were recorded and compared with survival data from the Scandiatransplant registry. In total, LTx after allo-SCT had been performed in 13 patients. Allo-SCT was done because of AML (n = 6), CML (n = 3), ALL (n = 2), immunodeficiency (n = 1) and aplastic anemia (n = 1). All developed clinical cGVHD, with median interval from allo-SCT to LTx of 8.2 (0.7-16) years. Median age at LTx was 34 (16-55) years, and the median postoperative observation time was 4.2 (0.1-15) years. Two patients died, one due to septicemia, the other of relapsing leukemia, after 2 and 14 months, respectively. Four developed BOS, one of these was retransplanted. The survival did not significantly differ from the survival in matched LTx controls, being 90% 1 year and 75% 5 years after LTx compared with 85% and 68% in the controls. We therefore suggest that LTx may be considered in carefully selected patients with BOS due to cGVHD after allo-SCT. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/3815377
- author
- Holm, A. M. ; Riise, G. C. ; Hansson, Lennart LU ; Brinch, L. ; Bjortuft, O. ; Iversen, M. ; Simonsen, S. and Floisand, Y.
- organization
- publishing date
- 2013
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- allo-SCT, lung transplantation, survival
- in
- Bone Marrow Transplantation
- volume
- 48
- issue
- 5
- pages
- 703 - 707
- publisher
- Nature Publishing Group
- external identifiers
-
- wos:000318699800014
- scopus:84877649542
- pmid:23064037
- ISSN
- 1476-5365
- DOI
- 10.1038/bmt.2012.197
- language
- English
- LU publication?
- yes
- id
- 1d6105d5-0705-4a2e-9e59-85a9b3682050 (old id 3815377)
- date added to LUP
- 2016-04-01 10:52:14
- date last changed
- 2022-04-04 22:08:22
@article{1d6105d5-0705-4a2e-9e59-85a9b3682050,
abstract = {{Chronic GVHD (cGVHD) associated bronchiolitis obliterans syndrome (BOS) is a serious complication after allo-SCT, and lung transplantation (LTx) may be the ultimate treatment option. To evaluate this treatment, data on all patients with LTx after allo-SCT ever performed in Sweden, Norway, Denmark and Finland were recorded and compared with survival data from the Scandiatransplant registry. In total, LTx after allo-SCT had been performed in 13 patients. Allo-SCT was done because of AML (n = 6), CML (n = 3), ALL (n = 2), immunodeficiency (n = 1) and aplastic anemia (n = 1). All developed clinical cGVHD, with median interval from allo-SCT to LTx of 8.2 (0.7-16) years. Median age at LTx was 34 (16-55) years, and the median postoperative observation time was 4.2 (0.1-15) years. Two patients died, one due to septicemia, the other of relapsing leukemia, after 2 and 14 months, respectively. Four developed BOS, one of these was retransplanted. The survival did not significantly differ from the survival in matched LTx controls, being 90% 1 year and 75% 5 years after LTx compared with 85% and 68% in the controls. We therefore suggest that LTx may be considered in carefully selected patients with BOS due to cGVHD after allo-SCT.}},
author = {{Holm, A. M. and Riise, G. C. and Hansson, Lennart and Brinch, L. and Bjortuft, O. and Iversen, M. and Simonsen, S. and Floisand, Y.}},
issn = {{1476-5365}},
keywords = {{allo-SCT; lung transplantation; survival}},
language = {{eng}},
number = {{5}},
pages = {{703--707}},
publisher = {{Nature Publishing Group}},
series = {{Bone Marrow Transplantation}},
title = {{Lung transplantation for bronchiolitis obliterans syndrome after allo-SCT}},
url = {{http://dx.doi.org/10.1038/bmt.2012.197}},
doi = {{10.1038/bmt.2012.197}},
volume = {{48}},
year = {{2013}},
}